Novo's Wegovy takes a hit from compounders, but company expects faster second-half growth
As the U.S. GLP-1 market is in a period of transition, Novo Nordisk is holding out hope for faster growth in the second half of 2025.
As the U.S. GLP-1 market is in a period of transition, Novo Nordisk is holding out hope for faster growth in the second half of 2025.
